Founded in 2007, Epizyme brings together academic and industry leaders to develop novel, molecularly targeted drugs through epigenetic research. Its product candidates include TAZVERIK, an approved inhibitor of the EZH2, and pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias and PRMT5 inhibitor. Recently acquired by Ipsen, Epizyme now operates as an Ipsen company, committed to delivering innovative treatment options to underserved patients in oncology, neuroscience, and rare disease.